Acelarin First Line Randomised Pancreatic Study

PHASE2/PHASE3SuspendedINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

September 30, 2020

Study Completion Date

December 31, 2022

Conditions
Pancreatic Acinar CarcinomaPancreatic Neoplasms
Interventions
DRUG

Acelarin

825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

DRUG

Gemcitabine

1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Trial Locations (1)

L69 3GL

Cancer Research UK Liverpool Cancer Trials Unit, Liverpool

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

University of Liverpool

OTHER

lead

The Clatterbridge Cancer Centre NHS Foundation Trust

OTHER